Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads while reducing turnaround times. More importantly, digital pathology enables the use of artificial intelligence (AI)-assisted image analysis solutions, unlocking even more benefits for pathologists. Whole slide images can be viewed in high quality on a computer screen and with software that allows fluid panning and zooming, enabling pathologists to see better and more. These viewing functionalities, combined with AI, can help users discover patterns or markers they may have missed if using traditional, manual methods. Machine learning can also detect features beyond the assessment of traditional histopathology, such as prognosis. Now, a clinical AI solution supports pathologists by automating breast cancer grading.

Aiforia Technologies (Cambridge, MA, USA) has launched a new CE-IVD-marked clinical AI solution for breast cancer grading. Aiforia Breast Cancer Grading AI solution is a part of the Aiforia Breast Cancer Suite, which also includes CE-IVD marked AI models for breast cancer biomarkers and the Aiforia Clinical Suite Viewer. This complete solution offers a fully digital cockpit for breast cancer diagnostics, supporting the entire diagnostic workflow. The new CE-IVD marked AI solution automates breast cancer grading by supporting pathologists with the help of five separate AI models. It accurately identifies invasive carcinoma and ductal carcinoma in situ (DCIS). It also objectively detects and scores mitotic count, tubular formation, and nuclear pleomorphism, consistent with the Nottingham Grading System. This addresses the key challenges of manual grading, such as variability and time constraints.

“We are proud to announce the latest CE-IVD marked solution in our breast cancer diagnostics portfolio, making Aiforia Breast Cancer Suite the most comprehensive AI toolkit on the market,” said Jukka Tapaninen, CEO of Aiforia Technologies. “The new solution brings substantial time savings to the pathologists when reporting the histological grade and enhances diagnostic accuracy and consistency across cases, leading to increased confidence in clinical decision-making.”

Related Links:
Aiforia Technologies